Frontiers in Health Informatics
ISSN-Online: 2676-7104
www.healthinformaticsjournal.com
2024; Vol 13: Issue 7
Open Access

Mucoadhesive Gastroretentive Drug Delivery Systems: Challenges And Opportunities In Pharmaceutical Development

Ravi Jayant[1], Dr. Sokindra Kumar[1] , Dr. Sachin Kumar[2]
[1] Faculty of Pharmacy, Swami Vivekanand Subharti University, Meerut-250005, India
[2] NKBR College of Pharmacy and Research Centre, Meerut-245206, India

Cite this paper as: Ravi Jayant, Dr. Sokindra Kumar , Dr. Sachin Kumar (2024). Mucoadhesive Gastroretentive Drug Delivery Systems: Challenges And Opportunities In Pharmaceutical Development. *Frontiers in Health Informatics*, *13 (7) 572-587*

ABSTRACT
Mucoadhesive gastroretentive drug delivery systems (MGDDSs) represent new vehicles that are used for enhancing gastric residence of the drug, thereby increasing its bioavailability and therapeutic response. These drug delivery systems exploit the adhesive interaction between the dosage form and gastrointestinal mucosa to prolong the drug's residence in the stomach. Despite the great promise associated with this system, formulation difficulties, scaling-up challenges, and inter- and intra-patient variability may represent some of the challenges facing the practical application of MGDDSs. The present review gives an overview of the mechanism, formulation strategies, and techniques of evaluation of MGDDS. In addition, the review discusses the challenges and opportunities regarding their pharmaceutical development and has pointed out their relevance to modern therapeutics.
Keywords: Mucoadhesive Gastroretentive Drug Delivery Systems (MGDDS), Controlled Drug Release, Bioadhesive Polymers, Gastric Retention, Pharmaceutical Innovations

INTRODUCTION

The gastrointestinal (GI) tract provides an environment for drug delivery that is highly dynamic and complex; with this comes great opportunities along with considerable challenges. Owing to its unique physiological conditions of pH, enzymatic activity, and transit times, it is often difficult to achieve an effective oral drug delivery system [1-4]. Traditional oral drug delivery systems generally exhibit low bioavailability of a drug due to their limited gastric retention time, which is the case with molecules that have a narrow absorption window in the upper GI tract or are labile in the distal intestines. This deficiency has motivated the development of gastroretentive drug delivery systems that can extend the retention time of the drug in the stomach for better therapeutic outcomes and patient benefit [5-7].

Different mechanisms, such as floating systems, swelling and expandable systems, and mucoadhesive systems, have been used to prolong the gastric retention period in the development of gastroretentive drug delivery system (GRDDS). Among them, mucoadhesive systems have been considered more favourably due to their potential ability to interact with the mucus layer lining the stomach. These systems utilize the concept of mucoadhesion-the adherence of the dosage form to the mucosal surface-through physical interactions like hydrogen bonding, van der Waals forces, and electrostatic interactions. This adhesion prevents the early emptying of the dosage form into the small intestine, enabling longer retention and sustained drug release [3, 8, 9]. The gastroretentive mucoadhesive drug delivery systems are under evaluation for various therapeutic applications. They have been successfully applied for the delivery of drugs used for various conditions such as gastric ulcers, infections by *Helicobacter pylori*, and chronic diseases requiring a controlled or prolonged drug release. This unique localization of drug delivery within the stomach by MGDDS makes it particularly suitable for drugs with a specific site of action or those drugs that are poorly soluble in an acidic gastric environment [3,

[8, 9].



Figure 1: Gastro-retentive drug delivery systems at a glance.

Mucoadhesion is the phenomenon where there is an interaction between the mucoadhesive polymer and the layer of mucus covering the lining of the stomach. Mucoadhesion consists of a contact phase where the dosage form is in close contact with the mucosal surface, and a consolidation phase where molecular interactions occur, such as hydrogen bonding and polymer chain entanglement. Mucoadhesion is dependent upon factors such as selection of polymer, molecular weight and charge, and flexibility of the polymer chain, in addition to physiological factors including mucin turnover, pH of the environment, and the presence of enzymes [10, 11]. Despite their great potential, various challenges persist in the development and application of MGDDS: individual differences with regard to their gastric conditions; possible irritation by some mucoadhesive polymers; and scalability of the production processes. The new formulation technology and polymer science have contributed considerably to a better design of more efficient and patient-friendly systems. Investigations into novel, biodegradable, and stimuli-responsive polymers further expand their potential [1-4].

This review covers the principles of mucoadhesion, the various strategies in the formulation of MGDDS, and the methods of assessing their performance. Further, the challenges and opportunities of these systems are discussed, underlining their revolutionary role in modern drug delivery. Overcoming current limitations and taking advantage of new technologies will enable the realization of the potential of MGDDS to change therapeutic strategy in many GI and systemic conditions.

Mechanisms of mucoadhesion

Mucoadhesion is a process by which the interaction of the drug delivery system and mucosal surfaces in the GIT becomes strong. It allows, during prolonged periods, the stay of a dosage form at the absorption site or the site of its action, thus enhancing its therapeutic activity. The mucoadhesive phenomenon of different systems can be divided, concerning its nature, into contact and consolidation stages, largely dependent on various physicochemical and biological factors [3, 4, 12].

Contact stage

The contact stage represents a real first contact between the dosage form and the mucosal surface. For effective adhesion,

the approaching of the dosage form near the mucosal layer in very close proximity is an unconditional requisite. Hydration of the mucoadhesive polymer forms an important criterion with this stage. These polymers uptake water upon contact with the moisture-providing mucosa resulting in swelling and subsequent softening. This enhances their surface area, allowing intimate contact with the mucosal surface. Wetting properties of the system also play a great role; dosage forms which possess good wettability are likely to spread over the mucosal surface and increase their interfacial area on the site of adhesion. From the external factors that are applied, the contact pressure during placement and duration of the dosage form with the mucosa act to enhance this stage [13, 14].

Consolidation stage

It follows that the consolidation step was after the formation of an initial contact and therefore consisted of establishing molecular interaction between the mucoadhesive system and the mucosa. Until now, the nature of such interactions has mainly been attributed to chemical and physical bonding mechanisms, including hydrogen bonds, electrostatic forces, van der Waals interactions, and hydrophobic forces. It has more contribution from hydrogen bonding that arises between the functional groups of the polymer-like hydroxyl, carboxyl, and amino groups and mucin in the layer. Electrostatic interactions are brought about by the difference in charges that exist between the polymer and the mucosa, and the van der Waals forces contribute to the stability of the adhesion. Also, the interpenetration of polymer chains into the mucosal glycoprotein network increases the mechanical strength of the bond [13, 14].



Figure 2: Mechanism of Mucoadhesion

Polymer properties and Physiological factors

Mucoadhesion depends on a variety of variables. Properties of the polymer are the major determinant. High molecular weight polymers, such as Carbopol and polyacrylic acid, present greater adhesiveness due to their possibility of forming an extensive network of bonds. Flexibility of the polymer chains further allows enough interpenetration with the components of mucosa. In addition, charge on the polymer affects adhesion in those cationic polymers, like chitosan, normally show great adhesion due to their affinity to the negatively charged mucosal surface.

Other important factors in the control of mucoadhesion are physiological. The availability of a longer contact period by the retention of a formulation for sometimes depends on the turnover time of the principal mucus secretion, which is mucin; a rapid mucin exchange may favour low retention or residence times for a mucoadhesive system. Local values

of pH and ionic strength within mucus are further influential concerning the alteration of structural features of interfacial polymer-mucin interactions and may influence interaction. Conditions can be such that acidic or alkaline conditions may enhance or weaken hydrogen bonding and electrostatic interactions, respectively. In a nutshell, mucoadhesion is a dynamic, complicated process interrelated with both the properties of the polymers involved and physiological considerations. Understanding the mechanisms at play is imperative to develop active mucoadhesive systems which will overcome issues pertaining to gastrointestinal drug delivery. In this respect, optimization of both contact and consolidation steps bears strong potential for the improvement of therapeutic efficacy of mucoadhesive gastroretentive drug delivery systems [13-16].

Formulation approaches for MGDDS

The development of mucoadhesive gastroretentive drug delivery systems is quite cumbersome and involves the judicious selection of polymers and techniques of fabrication. Materials and methods adopted decide the success of the system to ensure prolonged gastric retention, thereby assuring effective drug delivery with patient compliance. Few important strategies involved in the design of MGDDS are dealt with, focusing on the role of polymers, types of systems, and the release mechanism [17].

1. *Mucoadhesive Polymers*

The properties of the polymers used in the formulation of MGDDS are greatly responsible for its effectiveness. Polymers facilitate adhesion to the gastric mucosa and are mainly responsible for the control of drug release. These can be further categorized into synthetic, natural, and modified polymers, each with unique advantages.

- ***Synthetic Polymers****:* Synthetic polymers such as polyacrylic acid, Carbopol, and polyvinyl alcohol are commonly used for MGDDS due to their very high strength of mucoadhesion. These could offer strong hydrogen bonding with ionic interactions of mucosal layer, enhancing the chances of robust adhesions coupled with sustained retention. Moreover, their chemical structure has the option for modification with functional groups to enhance their properties [18, 19].
- ***Natural Polymers****:* These natural polymers are very popular because of their biocompatibility and biodegradability. Natural polymers such as chitosan, pectin, alginate, and guar gum have been extensively used in this regard. Chitosan is a cationic polysaccharide and hence is most effective in the gastric environment due to its ability to interact with the negatively charged mucosal surface. Pectin and alginate are usually used for their gelling property, enhancing the prolonged adhesion and thereby providing controlled drug release. Natural polymers are also attractive due to their lower toxicity and minimal environmental impact [18, 19].
- ***Modified Polymers****:* It will also be noticed that there are modified polymers aiming for enhancements in adhesive interactions with mucosa, including thiolated polymers. Thus, thiol groups will interact with mucin glycoproteins through the formation of disulfide bonds, developing stronger and durable adhesions. The modified polymer displays advantages in drug delivery application such as extended retention time under undesirable conditions [18, 19].

2. *Types of MGDDS*

The systems of MGDDSs are designed in various formats, each prepared to respond to specific therapeutic or delivery requirements. Selection could be due to the nature of the drug, target disease site, or even patient convenience [18-21].

- ***Tablets****:* Mucoadhesive tablets have compact dosage form, are easy to manufacture. They are formulated with bioadhesive polymers for extended gastric retention. Such systems are highly suitable for drugs requiring sustained release in a period of several hours.
- ***Microspheres****:* Mucoadhesive microspheres have features such as controlled drug release with enhanced surface area and adhesion. These will be especially suitable for drugs that exhibit low solubility or a short half-life.

- ***Films and Patches***: These flexible, thin systems are suitable for both local treatment and systemic delivery. Films and patches adhere to the gastric mucosa, ensuring controlled release of the drugs.
- ***Hydrogels****:* Hydrogels are three-dimensional, water-swollen networks that adhere to the mucosa, thus providing controlled drug release. The swelling of hydrogels in gastric fluids is supposed to enhance their adhesive properties and residence time.

3. *Release Mechanisms*

The mechanism by which MGDDS release drugs is another critical factor in their design. Different release mechanisms are employed based on the therapeutic requirements [22, 23]:

- ***Diffusion-Controlled Systems***: The drug diffuses out of the polymer matrix into the gastric fluid in these systems. The rate of release is influenced by the structure of the polymer and the solubility of the drug.
- ***Swelling-Controlled Systems****:* these systems depend on the swelling of the polymer in gastric fluids. In that, the swollen polymer matrix expands due to the absorption of water, creating pathways for drug diffusion.
- ***Erosion-Based Systems***: In erosion-based systems, the drug is released by degradation of the polymer matrix itself in the gastric environment. Such systems are useful for drugs requiring zero-order release kinetics.

In short, MGDDS development involves the use of advanced polymer science, novel design of delivery systems, and control of release mechanisms. It is with such approaches that MGDDS will be able to respond to challenges such as short gastric residence times and enhance the therapeutic efficacy of oral drug delivery systems.

Table 1: Types of Polymers Used in MGDDS

Polymer Type	Examples	Advantages
Synthetic Polymers	Polyacrylic acid, Carbopol, polyvinyl alcohol	High mucoadhesive strength, customizable chemical properties, consistent performance.
Natural Polymers	Chitosan, pectin, alginate, guar gum	Biocompatible, biodegradable, low toxicity, good environmental compatibility.
Modified Polymers	Thiolated polymers	Enhanced adhesion through disulfide bond formation, strong and durable mucoadhesion.

Table 2: Types of MGDDS

System Type	Description	Applications
Tablets	Compact systems formulated with bioadhesive polymers.	Sustained drug release, easy manufacturing, prolonged gastric retention.
Microspheres	Small spherical systems with high surface area.	Controlled drug release, effective for drugs with low solubility or short half-life.
Films and Patches	Thin, flexible dosage forms.	Local treatment and systemic delivery, controlled drug release.
Hydrogels	Swollen, water-absorbing polymer networks.	Enhanced adhesion and retention, controlled drug release.

Table 3: Drug Release Mechanisms in MGDDS

Release Mechanism	Description	Example Use
Diffusion-Controlled Systems	Drug diffuses from the polymer matrix into gastric fluid.	Prolonged release of water-soluble drugs.
Swelling-Controlled Systems	Polymer absorbs water and expands, creating pathways for drug release.	Delivery of hydrophilic drugs with controlled diffusion.

Erosion-Based Systems	Polymer matrix erodes in gastric fluids, releasing the drug.	Zero-order drug release for consistent plasma drug levels over time.



Figure 3: Comparison of Drug Release at 8 Hours Across Formulations

Evaluation techniques for MGDDS

Performance evaluation of mucoadhesive gastroretentive drug delivery systems is an important task that will establish the efficacy, safety, and stability of the system. Full evaluation encompasses in vitro and in vivo studies that address several parameters like mucoadhesion strength, gastroretentive behaviours, drug release profile, and stability at physiological conditions. These techniques of evaluation not only validate the performance of the formulation but also help in optimizing its design for clinical applications. Following are the major techniques adopted to analyse MGDDS under some key performance parameters [24-27].

1. *Mucoadhesion Strength*

Mucoadhesion strength can be regarded as one of the defining features of MGDDS and an important determinant of its performance. Mucoadhesion strength is the potential of the formulation to adhere to the mucosal surface and resist detachment for a longer period, thus ensuring prolonged gastric retention [28, 29].

- ***In Vitro Methods****:* Some other general, basic techniques apply in vitro tests used everywhere are easy to perform and repeat. One of the current instruments used for mucoadhesive strength is a texture analyser. It measures the force of detaching the polymer or a given formulation from the mucosal surface and gives important facts about adhesion strength. By using a rotating cylinder method, dynamic testing of a formulation with its attachment ability on a simulated mucosal surface can be considered in respect to gastric motility. The flow-through method evaluates mucoadhesion by simulating the fluid flow over a mucosal surface; in this way, adhesion may be studied under conditions quite similar to peristaltic movements in the stomach [27-29].
- ***Ex Vivo Methods****:* Ex vivo methods involve the testing of formulations for their adhesion to excised mucosal tissues that closely resemble human gastric conditions, like that from a pig's stomach or bovine mucosa. In such tests, adhesive strength is quantified through a description of the force that could be applied to detach the formulation from the tissue. This approach will indeed present more realistic data when related to in vitro

techniques since it takes into consideration both the biochemical composition and texture of actual mucous membranes [27-29].

2. *Gastroretentive Behaviour*

MGDDS relies on gastroretentive behaviour in order to be effective, as it relates directly to the residence duration of the formulation within the stomach. This parameter is therefore often tested by in vitro and in vivo techniques, which are appropriate for a specific gastroretentive mechanism [27, 30, 31].

- ***Buoyancy Tests****:* Buoyancy is among the four cardinal attributes for floating. The test describes the behaviour of the dosage form; that is, floating from simulated gastric fluid over lengthy periods. Some general evaluated parameters include time for start floating and the duration required for formulations to float (total floating duration. Floating formulations should float up immediately and continue to stay afloat regularly for the desired period-end [28, 29].
- ***Radiographic Imaging****:* In vivo radiographic imaging has emerged as one of the effective methods to investigate the gastroretentive performance of MGDDS. The formulations are labelled with a contrast agent or radiopaque markers, and following administration, it is traced in the gastrointestinal tract through X-rays. It is the direct evidence of gastric residence time and gastric position of the dosage form and gives many important features on the performance under physiological conditions [28, 29].



Figure 4: Comparison of Bioavailability Across Formulations

3. *Drug Release Studies*

Drug release studies form an integral part of the understanding the release kinetics and mechanism behind drug delivery from MGDDS. Such a study ensures that the formulation meets the desired therapeutic objective, whether it is sustaining or controlling the drug release [25, 32, 33].

- ***Dissolution Testing****:* Dissolution studies in the stomach are emulated by carrying out the experiment in simulated gastric fluids, such as pH 1.2 buffer. The release profile is thus studied over time to determine how fast or slow and to what extent the drug is being released from the system. Such dissolution studies are an important part of predicting in vivo behaviour and optimization in the design of a formulation.

- ***Mathematical Modelling for Release Kinetics****:* Mathematical models are applied to analyse drug release data and identify the release mechanism. Common models include:
    - ***Zero-Order Kinetics****:* Indicates a constant drug release rate over time, ideal for maintaining steady plasma drug levels.
    - ***First-Order Kinetics****:* Suggests a release rate proportional to the remaining drug concentration.
    - ***Higuchi Model****:* Describes drug diffusion through a matrix system.
    - ***Korsmeyer-Peppas Model****:* Explains release mechanisms, including diffusion and erosion, through an exponential equation [34-37].

4. *Stability Studies*

Stability studies will ensure the integrity and performance of MGDDS under various physiological and storage conditions. These studies will be very important in defining the shelf life and reliability of the formulation [34-38].

- ***Testing Under Varying pH Conditions***: Because the pH of the stomach may vary-for instance, between meals or under pathological conditions-MGDDS are also tested at different pH values to assess their integrity and mucoadhesive properties. The formulations should be stable within this range and maintain their functionality.
- ***Enzymatic Stability****:* The stomach is a host to a variety of enzymes, such as pepsin, which could have a degrading effect on certain polymers. Stability studies will define the resistance of the formulation to enzymatic degradation and thus guarantee its performance for the period of intended residence.

The techniques for the evaluation of MGDDS include various in vitro and in vivo methods that explore a particular aspect of the performance of the formulation. Mucoadhesion strength tests confirm the adhesive potential, while gastroretentive behaviour evaluations confirm the prolonged retention within the stomach. Drug release studies provide information on kinetics and the mechanism of drug delivery, while stability studies assure the formulation's reliability under physiological and storage conditions. Together, these evaluations provide a comprehensive understanding of MGDDS, guiding their optimization and successful application in pharmaceutical development [39-41].



Figure 5: Adhesion Strength Comparison Across Formulations

Table 4: Mucoadhesion Strength Evaluation Methods

Method Type	Technique	Description
***In Vitro* Methods**	Texture Analyzer	Measures the force required to detach the formulation from a mucosal surface.
	Rotating Cylinder Method	Simulates gastric motility by evaluating adhesion under dynamic conditions.
	Flow-Through Method	Assesses adhesion strength under simulated fluid flow conditions, mimicking peristaltic motion.
***Ex Vivo* Methods**	Adhesion Testing on Tissues	Measures adhesive strength using excised mucosal tissues (e.g., pig or bovine stomach mucosa).

Table 5: Gastroretentive Behaviour Evaluation Techniques

Evaluation Type	Technique	Description
***In Vitro* Testing**	Buoyancy Tests	Measures floating lag time and total floating duration in simulated gastric fluids.
***In Vivo* Testing**	Radiographic Imaging	Tracks the gastric residence time and location of radiopaque formulations using X-rays.

Challenges in pharmaceutical development

Mucoadhesive gastroretentive drug delivery systems indeed hold great promise in improving the therapeutic potential of drugs by increasing their gastric residence time. However, the formulation and clinical development of such systems are fraught with several challenges that can affect their overall success. These challenges include formulation complexities, physiological variations, patient compliance issues, manufacturing and scalability, and regulatory and quality assurance concerns. The key to overcoming these challenges requires a deep understanding of each [42-44].

1. *Formulation Challenges*

The critical balance between the mucoadhesive strength and drug release performance remains one of the most important issues that must be overcome during the development of MGDDS. While sufficient mucoadhesion is required to retain the dosage form in the stomach, excessive adhesiveness may compromise the drug release kinetics, leading to unsatisfactory therapeutic outcomes. Similarly, weak adhesion can result in the premature evacuation of the dosage form from the stomach, reducing drug bioavailability. Another big challenge is the compatibility of the polymers with the APIs. The polymers in MGDDS should not affect the stability or bioactivity of the drug. Some polymers can react with APIs, affecting their efficacy or resulting in undesirable side effects. Additionally, physicochemical properties of the polymer, such as molecular weight, charge, and solubility, should be optimized to achieve a stable formulation with required performance [45, 46].

2. *Physiological Variations*

These minor physiological differences greatly impact the overall efficacy of MGDDS, thereby making their performance less predictable among diverse groups of patients. For example, differences in the mucosal turnover rate, and gastric emptying time may decisively affect mucoadhesive strength and the retention of a dosage form. Patients with quicker mucin turnover, for example, may have lower adhesion and hence lower gastric residence times. Dietary habits and some diseased states further contribute to the variability in gastric residence time. For instance, a high-fat meal that reduces

the rate of gastric emptying may increase the dwell time of MGDDS. conversely, gastroparetic or diarrheic conditions may adversely affect the performance of the system. Thereby, these physiological factors complicate the standardization of MGDDS and call upon formulation development capable of adapting under such variability [47, 48].

3. *Patient Compliance*

In this way, the success of any drug delivery system essentially depends on patient compliance; MGDDS is no exception in that. Large-sized dosage forms may present discomfort for the patients, especially for those who have difficulties with swallowing. This could be considered a serious hindrance for acceptance of, and further adherence to, treatment regimens. Sensitivity to some mucoadhesive polymers is also possible. Irritation of the gastric mucosa or allergic reactions by some polymers in hypersensitive individuals has discouraged their use. Minimizing adverse effects to develop patient-friendly MGDDS remains one of the priorities to enhance compliance.

4. *Manufacturing and Scalability*

MGDDS fabrication normally requires complicated processes that need Stringent control of parameters such as the concentration of polymer, the amount of drug loaded inside, and the degree of crosslinking. Most of these methods are difficult to scale from the laboratory to industrial production because maintaining consistency and quality at larger scales is very hard; moreover, high raw materials costs, especially for advanced polymers or modified ones. Normally, such costs, being high, are transferred and shifted to the consumer, as usual, making the treatment with such devices less accessible. Moreover, there are regulatory challenges to be met for fulfilling the stringent requirements of safety and efficacy, adding more time and cost to bringing these systems to the market. Simplification of manufacturing processes with assured product quality is a key area of focus for both researchers and pharmaceutical companies [47, 48].

5. *Regulatory and Quality Assurance*

The regulatory landscape of mucoadhesive systems remains underdeveloped, lacking uniform guidelines on their evaluation and approval. This uncertainty makes the life of a manufacturer difficult and postpones the development and commercialization of MGDDS. Well-structured regulatory frameworks addressing the specific characteristics of mucoadhesive systems are needed if these systems are to see wider acceptance. Ensuring consistency in quality and performance during large-scale production is another major challenge. Properties of raw materials, conditions during the process, and batch-to-batch variability are just some of the factors that may alter the performance of the MGDDS. Close quality assurance through critical process parameter monitoring to rigorous post-production testing is done to ensure product integrity [37, 44, 48].

In a nutshell, whereas MGDDS have a lot of benefits in enhancing drug delivery, their development and commercialization do not come devoid of obstacles. Overcoming formulation difficulties, accounting for physiological variation, improving patient compliance, manufacturing facilitation, and bridging regulatory landscapes are some important ways of overcoming these barriers. These challenges, once solved, will help open full perspectives for MGDDS toward successful research and pharmaceutical applications by permitting newer, more effective therapies in an easily acceptable form to patients.

Opportunities in pharmaceutical development

While there are challenges in mucoadhesive gastroretentive drug delivery systems, these platforms can hold immense opportunities for innovation in pharmaceutical development. By tapping into the power of material science, formulation techniques, and drug delivery technologies, MGDDS can address unmet medical needs and improve therapeutic outcomes. The following opportunities give a dimension of growth and development that is possible in this area.

1. *Targeted Drug Delivery*

The most exciting prospects for MGDDS relate to the possibility of targeted drug delivery, particularly for those drugs that exhibit narrow absorption windows in the upper parts of the GI tract. Such systems can keep the drugs in the stomach for a longer time, thereby assuring extended and localized release. This is particularly advantageous for drugs that are

poorly absorbed in the lower GI tract or sensitive to degradation in alkaline conditions. MGDDS can also be used for local treatment of gastric disorders such as ulcers, gastritis, and infections by Helicobacter pylori. By maintaining the drug at the site of action, these systems can deliver therapeutic concentrations to the affected area and reduce systemic side effects, with an improvement in efficacy. Mucoadhesive systems, for instance, can be used to deliver antibiotics directly to the stomach for the eradication of H. pylori, where it can reside for a longer period of time [48, 49].

2. *Novel Polymers*

Development of new polymers is another one of the innovative areas in MGDDS. From these, smart polymers-approaching environmental stimuli such as pH, temperature, and enzymatic activity-predict an immense potential. Dynamic properties modify drug release and adhesion in response to changing circumstances of the gastric environment. For example, pH-responsive polymers adjust their swelling in the acidic stomach for optimal mucoadhesion and controlled drug release. In contrast, temperature-sensitive polymers gel at body temperature, enhancing their retention and stability. Introduction of such smart materials improved not only the performance of MGDDS but also extended their applicability to a wide range of therapeutic scenarios [10, 34, 50, 51].

3. *Combination Therapies*

Other exciting opportunities for MGDDS involve combination therapies where many drugs are co-delivered for synergistic effects. These systems can be made to release drugs sequentially or simultaneously, depending on the therapeutic requirements. This approach has particular value in the management of chronic diseases, including diabetes, cardiovascular disorders, and infections, which often require combination therapy. For instance, a single MGDDS can be used in the administration of an antacid and an antibiotic for the treatment of gastric ulcers caused by H. pylori. The antacid would neutralize stomach acid, thereby providing a very favourable environment for the action of the antibiotic. Such multi-drug systems simplify dosing regimens, enhance patient adherence, and improve treatment outcomes [11, 49, 52, 53].

4. *Patient-Centric Designs*

Patient compliance is a critical factor for the success of any drug delivery system, and MGDDS are no exception. The key opportunity lies in developing compact systems that are more palatable while maintaining mucoadhesive and drug delivery properties. Recent developments in polymer science and formulation techniques have made it possible to develop compact systems which can be easily swallowed with minimum discomfort. Besides, MGDDS can be tailored to meet specific patient needs, such as paediatric or geriatric populations who may have difficulty swallowing large tablets. Flavour masking, color customization, and flexible dosage forms like thin films and patches can further enhance patient acceptance. These patient-centric designs improve adherence and ensure that therapeutic benefits are maximized [5].

5. *Technological Integration*

Advanced technologies being integrated into the development of MGDDS open new frontiers in innovation. Among them, 3D printing is a strong tool for the precise fabrication of complex drug delivery systems. It allows the layer-by-layer construction of MGDDS and thus permits customization of drug release profiles, mucoadhesive properties, and structural designs to meet the needs of individual patients [6, 54-56]. Besides, nanotechnology will enhance the performance of MGDDS by improving drug loading, stability, and release kinetics. The nanoparticles embedded in the mucoadhesive matrix can be designed for controlled drug release and targeted delivery, further expanding the versatility of these systems. For example, the MGDDS based on nanoparticles can be designed to deliver an anticancer drug directly to gastric tumours, reducing systemic toxicity. Technological development also allows the use of computational modelling and AI in order to optimize the formulations of MGDDS. AI-driven algorithms can predict various aspects of the performance of different polymer drug combinations, then identify the optimal manufacturing conditions and reduce the formulation development time and cost [54-56].

In all, MGDDS offer a wide avenue for innovative works in pharmaceutical development: targeting drug delivery and

localized treatment of GI-specific conditions, enhancement of drug bioavailability, the introduction of new responsive polymers to enhance mucoadhesion and drug release, and combination therapies enabling the effective management of complex diseases. Patient-centric designs and the integration of advanced technologies such as 3D printing and nanotechnology further broaden the scope of MGDDS, setting the stage for next-generation drug delivery systems. By capitalizing on these opportunities, researchers and pharmaceutical companies have the potential to reshape MGDDS into highly effective, patient-friendly solutions against an array of therapeutic challenges.

Future perspectives

The future of mucoadhesive gastroretentive drug delivery systems is bright, especially as formulation and application challenges associated with these systems are overcome by researchers and pharmaceutical developers. Innovations in materials science and formulation technologies hold the key to unlocking the next generation of MGDDS. A critical focus lies in the development of biodegradable and biocompatible polymers that enhance mucoadhesion without compromising safety or functionality. Such polymers can have a prolonged gastric residence time, while naturally being degraded and absorbed, reducing risks of long-term side effects. Another promising avenue for future research is the development of mucoadhesive systems that are bioinspired by natural adhesion mechanisms. These include the biological models from molluscs and geckos, which possess adhesive properties. Hence, bioinspired systems with mechanisms to emulate these phenomena could provide improved mucoadhesive strength, enhanced biocompatibility, and greater adaptability to the dynamic gastric environment. Longer-term in vivo studies have to be performed to establish safety and efficacy fully. The majority of current research is focused on relatively short-term assessments, which may not pick up effects resulting from prolonged use or repeated administration. These in vivo studies on holistic approach shall, therefore, enable the researchers to give more solid data regarding how MGDDS interacts with the gastric mucosa over time, degradation pathways, and its impact on systemic drug delivery. Such would also help in the identification of unforeseen risks or complications that would be very critical towards regulatory approval [57, 58].

Another important step toward the betterment of MGDDS is the standardization of evaluation protocols. Till this date, there are no uniformly established testing methodologies for mucoadhesive strength, gastroretentive behaviour, and release studies of active pharmaceutical ingredients in common practice. Standardization, however, will facilitate fast-forward processing in the regulation stages for newer formulations with tremendous swiftness in product development. All parameters concerning a particular method have to be uniform or match, hence allowing creativity with improved crosstalk inside scientific circles. Integration of AI and ML in the development of MGDDS might let loose transformative possibilities. Accordingly, these can help optimize formulation through predicting polymer-drug interactions, mucoadhesive strength, and ideal release kinetics. The behaviour that the computational models will undertake regarding the MGDDS, thanks to AI, can significantly simulate physiological conditions, thereby eliminating time-consuming trial-and-error experiments [59]. These phases of design and testing, if faster with the aid of AI/ML, could help reduce the overall cost and hence improve the whole drug development process. In conclusion, advances in material science, bio-inspired design, thorough in vivo testing, standard evaluation protocols, and integration with advanced computational tools will be part of shaping the future of MGDDS. Works towards this direction shall meet the realization of MGDDS and their ultimate translation to fabricating more active and patient-compliant drug delivery system.

CONCLUSION

Mucoadhesive gastroretentive drug delivery systems have huge promise to act as a transformational approach in the field of oral drug delivery and surmount some critical limitations that have haunted conventional dosage forms. Enhanced gastric retention with controlled release will contribute to an increase in drug bioavailability, particularly those independent of narrow absorption windows and those degradable through passage via the lower GI region. The ability of MGDDS to localize drug delivery into the stomach improves therapeutic efficiency by reducing systemic adverse effects thus, making them ideal in diseases such as gastric ulcers, Helicobacter pylori infections, and other diseases necessitating chronic therapy. Despite the promise exhibited so far, the successful development and clinical exploitation

of MGDDS is not without challenges. Attention has to be paid to issues such as the attainment of optimum mucoadhesive strength, compatibility of polymers with active pharmaceutical ingredients, and physiological variability among patients. Besides these, regulatory hurdles, such as a lack of uniform evaluation protocols, further complicate their development. In addition, scalability and cost of production are still the main challenges before their wide acceptance. However, the future of the MGDDS is bright, with continued advancements in materials science and pharmaceutical technology. The development of biodegradable, biocompatible, and stimuli-responsive polymers alone has expanded their scope. Bioinspired adhesion mechanisms and the introduction of nanotechnology further develop their capabilities. Furthermore, the design and optimization of formulations using artificial intelligence and machine learning will promise to accelerate research while reducing costs. Conclusion: MGDDS thus present a very promising avenue for improving drug delivery and therapeutic outcomes. With their targeted, efficient, and patient-friendly solutions, they have the potential to revolutionize pharmaceutical development. If the current challenges are overcome by serious research and technological innovation, MGDDS may turn out to be a cornerstone in the future of drug delivery systems for opening up newer avenues towards effective and accessible healthcare solutions.

FUNDING

Nil

DECLARATION OF INTEREST

None declared.

REFERENCES

1. Chun M-K, Cho C-S, Choi H-K. Mucoadhesive drug carrier based on interpolymer complex of poly(vinyl pyrrolidone) and poly(acrylic acid) prepared by template polymerization. Journal of Controlled Release. 2002;81(3):327-34.
2. Chun M-K, Cho C-S, Choi H-K. Mucoadhesive microspheres prepared by interpolymer complexation and solvent diffusion method. International Journal of Pharmaceutics. 2005;288(2):295-303.
3. Kavitha K, Kumar MR, Singh SJ. Novel mucoadhesive polymers-a review. Journal of Applied Pharmaceutical Science. 2011(Issue):37-42.
4. Khutoryanskiy VV. Advances in mucoadhesion and mucoadhesive polymers. Macromolecular bioscience. 2011;11(6):748-64.
5. Bhowmick A, Saha T, Karmoker JR, Reza MS. Design of experiment (doe) approach to prepare, characterize and optimize the gastroretentive mucoadhesive microspheres of repaglinide. Bangladesh Pharmaceutical Journal. 2019;22(2):135-45.
6. Gaur PK, Mishra S, Kumar A, Panda BP. Development and optimization of gastroretentive mucoadhesive microspheres of gabapentin by Box–Behnken design. Artificial Cells, Nanomedicine, and Biotechnology. 2014;42(3):167-77.
7. Jain SK, Awasthi AM, Jain NK, Agrawal GP. Calcium silicate based microspheres of repaglinide for gastroretentive floating drug delivery: preparation and in vitro characterization. J Control Release. 2005;107(2):300-9.
8. Frakolaki G, Giannou V, Kekos D, Tzia C. A review of the microencapsulation techniques for the incorporation of probiotic bacteria in functional foods. Crit Rev Food Sci Nutr. 2021;61(9):1515-36.
9. Smart JD. The basics and underlying mechanisms of mucoadhesion. Advanced drug delivery reviews. 2005;57(11):1556-68.
10. Ekama SO, Ilomuanya MO, Azubuike CP, Bamidele TA, Fowora MA, Aina OO, et al. Mucoadhesive Microspheres of Maraviroc and Tenofovir Designed for Pre-Exposure Prophylaxis of HIV-1: An in vitro Assessment of the Effect on Vaginal Lactic Acid Bacteria Microflora. HIV/AIDS (Auckland, NZ). 2021;13:399-413.
11. El-Leithy ES, Shaker DS, Ghorab MK, Abdel-Rashid RS. Optimization and characterization of diclofenac sodium microspheres prepared by a modified coacervation method. Drug Discov Ther. 2010;4(3):208-16.

12. Rajput G, Majmudar F, Patel J, Patel K, Thakor R, Patel B, et al. Stomach specific mucoadhesive tablets as controlled drug delivery system–A review work. Int J Pharm Biol Res. 2010;1(1):30-41.
13. das Neves J, Bahia MF, Amiji MM, Sarmento B. Mucoadhesive nanomedicines: characterization and modulation of mucoadhesion at the nanoscale. Expert Opin Drug Deliv. 2011;8(8):1085-104.
14. Smart JD. The basics and underlying mechanisms of mucoadhesion. Adv Drug Deliv Rev. 2005;57(11):1556-68.
15. Carlson TL, Lock JY, Carrier RL. Engineering the Mucus Barrier. Annu Rev Biomed Eng. 2018;20:197-220.
16. Edsman K, Hägerström H. Pharmaceutical applications of mucoadhesion for the non-oral routes. J Pharm Pharmacol. 2005;57(1):3-22.
17. Marczynski M, Kimna C, Lieleg O. Purified mucins in drug delivery research. Adv Drug Deliv Rev. 2021;178:113845.
18. Park H, Robinson JR. Mechanisms of mucoadhesion of poly(acrylic acid) hydrogels. Pharm Res. 1987;4(6):457-64.
19. Pham QD, Nöjd S, Edman M, Lindell K, Topgaard D, Wahlgren M. Mucoadhesion: mucin-polymer molecular interactions. Int J Pharm. 2021;610:121245.
20. Aspinall SR, Parker JK, Khutoryanskiy VV. Role of mucoadhesive polymers in retention of toothpaste in the oral cavity. Colloids Surf B Biointerfaces. 2021;208:112104.
21. Harding SE. Mucoadhesive interactions. Biochem Soc Trans. 2003;31(Pt 5):1036-41.
22. Lin YJ, Shatkin JA, Kong F. Evaluating mucoadhesion properties of three types of nanocellulose in the gastrointestinal tract in vitro and ex vivo. Carbohydr Polym. 2019;210:157-66.
23. Mura P, Maestrelli F, Cirri M, Mennini N. Multiple Roles of Chitosan in Mucosal Drug Delivery: An Updated Review. Mar Drugs. 2022;20(5).
24. Abd El-Aziz MF, Ismail S, Tadros MI, Elnabarawi MA. Alfuzosin hydrochloride-loaded low-density gastroretentive sponges: development, in vitro characterization and gastroretentive monitoring in healthy volunteers via MRI. Pharm Dev Technol. 2020;25(5):566-78.
25. Dhaliwal S, Jain S, Singh HP, Tiwary AK. Mucoadhesive microspheres for gastroretentive delivery of acyclovir: in vitro and in vivo evaluation. Aaps j. 2008;10(2):322-30.
26. Farhadnejad H, Mortazavi SA, Jamshidfar S, Rakhshani A, Motasadizadeh H, Fatahi Y, et al. Montmorillonite-Famotidine/Chitosan Bio-nanocomposite Hydrogels as a Mucoadhesive/Gastroretentive Drug Delivery System. Iran J Pharm Res. 2022;21(1):e127035.
27. Kotreka UK, Adeyeye MC. Gastroretentive floating drug-delivery systems: a critical review. Crit Rev Ther Drug Carrier Syst. 2011;28(1):47-99.
28. Rump A, Tetyczka C, Littringer E, Kromrey ML, Bülow R, Roblegg E, et al. In Vitro and In Vivo Evaluation of Carbopol 71G NF-Based Mucoadhesive Minitablets as a Gastroretentive Dosage Form. Mol Pharm. 2023;20(3):1624-30.
29. Senyigit ZA, Vetter A, Guneri T, Bernkop-Schnürch A. A comprehensive in vitro and in vivo evaluation of thiolated matrix tablets as a gastroretentive delivery system. Drug Deliv. 2011;18(6):405-14.
30. Murphy CS, Pillay V, Choonara YE, du Toit LC. Gastroretentive drug delivery systems: current developments in novel system design and evaluation. Curr Drug Deliv. 2009;6(5):451-60.
31. Senyigit ZA, Vetter A, Guneri T, Bernkop-Schnürch A. Gastroretentive particles formulated with thiomers: development and in vitro evaluation. J Drug Target. 2010;18(5):362-72.
32. Hou JY, Gao LN, Meng FY, Cui YL. Mucoadhesive microparticles for gastroretentive delivery: preparation, biodistribution and targeting evaluation. Mar Drugs. 2014;12(12):5764-87.

33. Turac IR, Porfire A, Iurian S, Crișan AG, Casian T, Iovanov R, et al. Expanding the Manufacturing Approaches for Gastroretentive Drug Delivery Systems with 3D Printing Technology. Pharmaceutics. 2024;16(6).
34. Freiberg S, Zhu XX. Polymer microspheres for controlled drug release. Int J Pharm. 2004;282(1-2):1-18.
35. Soppimath KS, Aminabhavi TM, Kulkarni AR, Rudzinski WE. Biodegradable polymeric nanoparticles as drug delivery devices. J Control Release. 2001;70(1-2):1-20.
36. Uhrich KE, Cannizzaro SM, Langer RS, Shakesheff KM. Polymeric systems for controlled drug release. Chem Rev. 1999;99(11):3181-98.
37. Varde NK, Pack DW. Microspheres for controlled release drug delivery. Expert opinion on biological therapy. 2004;4(1):35-51.
38. Khattab A, Zaki N. Optimization and Evaluation of Gastroretentive Ranitidine HCl Microspheres by Using Factorial Design with Improved Bioavailability and Mucosal Integrity in Ulcer Model. AAPS PharmSciTech. 2017;18(4):957-73.
39. Ahmad M, Adil N. Stability Studies of Two Different Polygelin (Haemaccel and Gelofusine) According to ICH Guidelines. PDA J Pharm Sci Technol. 2013;67(6):610-20.
40. González-González O, Ramirez IO, Ramirez BI, O'Connell P, Ballesteros MP, Torrado JJ, et al. Drug Stability: ICH versus Accelerated Predictive Stability Studies. Pharmaceutics. 2022;14(11).
41. Williams HE, Bright J, Roddy E, Poulton A, Cosgrove SD, Turner F, et al. A comparison of drug substance predicted chemical stability with ICH compliant stability studies. Drug Dev Ind Pharm. 2019;45(3):379-86.
42. Desai N. Challenges in development of nanoparticle-based therapeutics. Aaps j. 2012;14(2):282-95.
43. Gindy ME, Leone AM, Cunningham JJ. Challenges in the pharmaceutical development of lipid-based short interfering ribonucleic acid therapeutics. Expert Opin Drug Deliv. 2012;9(2):171-82.
44. Mueller C, Altenburger U, Mohl S. Challenges for the pharmaceutical technical development of protein coformulations. J Pharm Pharmacol. 2018;70(5):666-74.
45. Gaikwad SS, Morales JO, Lande NB, Catalán-Figueroa J, Laddha UD, Kshirsagar SJ. Exploring paediatric oral suspension development: Challenges, requirements, and formulation advancements. Int J Pharm. 2024;657:124169.
46. Jain KK. An Overview of Drug Delivery Systems. Methods Mol Biol. 2020;2059:1-54.
47. Sommer RJ. Phenotypic Plasticity: From Theory and Genetics to Current and Future Challenges. Genetics. 2020;215(1):1-13.
48. Wikberg M, Ulmius J, Ragnarsson G. Review article: Targeted drug delivery in treatment of intestinal diseases. Aliment Pharmacol Ther. 1997;11 Suppl 3:109-15.
49. El-Bary AA, Aboelwafa AA, Al Sharabi IM. Influence of some formulation variables on the optimization of pH-dependent, colon-targeted, sustained-release mesalamine microspheres. AAPS PharmSciTech. 2012;13(1):75-84.
50. Doelker E. Water-swollen cellulose derivatives in pharmacy. Hydrogels in medicine pharmacy. 1987;2:115-60.
51. Dupinder K, Seema S. Development and characterization of lovastatin loaded microspheres. International Research Journal of Pharmaceutical and Applied Sciences. 2013;3(5):197-205.
52. Grundy JS, Foster RT. The nifedipine gastrointestinal therapeutic system (GITS). Clinical pharmacokinetics. 1996;30(1):28-51.
53. Gupta R, Prajapati SK, Pattnaik S, Bhardwaj P. Formulation and evaluation of novel stomach specific floating microspheres bearing famotidine for treatment of gastric ulcer and their radiographic study. Asian Pacific Journal of Tropical Biomedicine. 2014;4(9):729-35.
54. Furlow B. Medical 3-D Printing. Radiol Technol. 2017;88(5):519ct-37ct.
55. Lambert KF, Whitehead M, Betz M, Nutt J, Dubose C. An Overview of 3-D Printing for Medical Applications. Radiol Technol. 2022;93(4):356-67.

56. Zeeshan F, Madheswaran T, Pandey M, Gorain B. Three-Dimensional (3-D) Printing Technology Exploited for the Fabrication of Drug Delivery Systems. Curr Pharm Des. 2018;24(42):5019-28.
57. Dhiman S, Philip N, Gurjeet Singh T, Babbar R, Garg N, Diwan V, et al. An Insight on Novel Approaches & Perspectives for Gastro-Retentive Drug Delivery Systems. Curr Drug Deliv. 2023;20(6):708-29.
58. Tripathi J, Thapa P, Maharjan R, Jeong SH. Current State and Future Perspectives on Gastroretentive Drug Delivery Systems. Pharmaceutics. 2019;11(4).
59. Mak KK, Pichika MR. Artificial intelligence in drug development: present status and future prospects. Drug Discov Today. 2019;24(3):773-80.